Takeda and Dr. Reddy''s Laboratories Enter Into Exclusive Collaboration to Promote and Distribute QDENGA® in India''s Pediatric and Adult Private Market

Collaboration focuses on disease awareness, promotion and distribution of Takeda’s dengue vaccine, across India’s private market for pediatric and adult vaccination, ahead of its anticipated availability in the first half of 2027. Collaboration combines Takeda’s global dengue and vaccine expertise with Dr. Reddy’s extensive healthcare network and commercial reach across India. Hyderabad, Telangana, Mumbai, Maharashtra, India --- Business Wire India Takeda Pharmaceutical Company Limited, through its Indian subsidiary Takeda Biopharmaceuticals India Private Limited (together referred to as “Takeda”) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today entered into a distribution agreement under which Dr. Reddy’s will promote and distribute Takeda’s dengue vaccine, QDENGA®, across India’s private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027. The collaboration follows the approval of QDENGA’s marketing authorization by India’s Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India’s first approved dengue vaccine, the approval marks an important milestone in the country’s efforts to strengthen dengue prevention and management.